Skip to Content

Posts tagged with "Business and Markets"

  • Biological News

    Good Craziness and Bad Craziness

    It’s fair to say that there’s a high level of excitement these days in biopharma (and the associated academic disciplines) due to the tools we have at our disposal these days. CRISPR and other gene-editing technologies, new looks at RNA, chromatin, and epigenetics, all sorts of unusual modes for altering cells and whole-animal phenotype… Read More
  • Business and Markets

    GSK Rearranges, Once More

    There have been a lot of announcements in the biopharma field this week, and I’m just now getting around to GlaxoSmithKline’s from a couple of days ago. The company announced that they’re dropping 30 R&D programs and refocusing the ones that are left. Cancer and immunology are now back in favor, and rare disease programs… Read More
  • Business and Markets

    AstraZeneca Gets the Bad News

    After writing about Merck’s successes (so far) in immuno-oncology, it’s time to write about AstraZeneca’s failure. When the rumors started flying about Pascal Soriot leaving the company, one of the speculations was that the MYSTIC trial of the company’s PD-L1 (Imfinzi, durvalumab) and CTLA4 (trememelimab) therapies might be… Read More
  • Business and Markets

    Chaos at AstraZeneca

    What on earth is going on over at AstraZeneca? The company has had plenty of wild ups and downs over the years, and managed to fight off a takeover attempt by Pfizer (and who else has managed that?) But in doing so, they made some pretty strong revenue projections (look what we’ll do if Pfizer… Read More
  • Biological News

    Hemophilia: A Proving Ground For Genetic Disease

    There’s very good news for Alnylam (and their partner Sanofi) this morning. They’ve been working on an RNAi approach to hemophilia (fitusiran), targeting expression of antithrombin, a protein which as the name implies which keeps blood from clotting by several different mechanisms. The clinical data that have just come out look very en… Read More
  • Business and Markets

    Does An Insurance Company Really Want to Develop New Therapies?

    Via David Shaywitz on Twitter, I’ve been seeing comments from the insurance company startup Clover Health that raised my eyebrows a bit. The misalignment between existing health insurers and their customers is that insurers view customers in terms of annual income instead of customer lifetime value. This is where (Vivek) Garipalli believes Cl… Read More
  • Business and Markets

    Following Up

    Here’s a question that I’m not sure if there’s a general answer to: if you’re putting together a drug discovery portfolio, what percentage of the projects should be new ones, and how many should be some form of follow-up? I say that there may not be a general answer because every place I’ve worked has… Read More
  • Business and Markets

    Head Counts and Profits

    I’ve been meaning to link to this article by Frank David at Endpoints, on “leaner and meaner” pharma organizations. For many years now, the story has been about how drug companies are shedding staff, but David says that more recently, that hasn’t been the whole story: From 2011 to 2015, employee numbers actually increased at… Read More
  • Business and Markets

    China’s Biopharma Rise

    This story by Damien Garde at Stat is well worth a look. It goes into a question that people in biopharma have been asking themselves for some years now: when does China move from a contractor to a competitor? This was brought home by the recent results at the ASCO meeting from Nanjing Legend, who… Read More
  • Business and Markets

    Mylan Begins Harvesting the Crop It’s Sown

    There’s an interesting fight going on inside Mylan Pharmaceuticals. They, of course, are the longtime generic drug maker whose EpiPen prices have (understandably) made them a lightning rod for complaints about drug pricing in general. This New York Times article will give you the flavor of the company, and most unappetizing it is: To understa… Read More
...345...